Alfons Grunenberg

USPTO Granted Patents = 26 (Patent Applications = 9)

CIPO Patents = 15 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 15)

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 130(Granted Patents)

Location History:

Dormagen, DE (1997 - 2018)
Wuppertal, DE (2017 - 2024)

Company Filing History:

Bayer Intellectual Property Gmbh

patents

4 out of 378

Bayer Pharma Aktiengesellschaft

patents

4. 3 out of 12,160

Bayer Aktiengesellschaft

Aicuris Gmbh + Co. Kg.

Bayer Schering Pharma Ag

patents

9. 1 out of 54

Bayer Animal Health Gmbh

Years Active: 1997-2025

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12503469 - Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate (2025-12-23),

2. RE49860 - Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient (2024-03-05),

3. RE49575 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient (2023-07-10),

4. 11203593 - Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate (2021-12-21),

5. 10662188 - Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate (2020-05-26),

6. 10633356 - Hydrates of substituted 5-fluoro-1H-pyrazolopyridines (2020-04-28),

7. 10399977 - Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient (2019-09-03),

8. 10364229 - Crystalline substituted 5-fluoro-1H-pyrazolopyridines and process for preparing (2019-07-30),

9. 10087183 - Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1h-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate (2018-10-02),

10. 10059707 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient (2018-08-28),

11. 9957232 - 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate (2018-05-01),

12. 9637459 - Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents (2017-05-02),

13. 9604948 - Process for preparing substituted 5-fluoro-1H-pyrazolopyridines (2017-03-28),

14. 9340535 - N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate (2016-05-17),

15. 8877933 - Thermodynamically stable form of a tosylate salt (2014-11-04),

Title: The Innovative Journey of Alfons Grunenberg: Pioneering Pharmaceutical Advancements

Introduction:

Alfons Grunenberg, a prolific inventor based in Wuppertal, DE, has left an indelible mark in the field of pharmaceuticals through his innovative creations. With a commitment to excellence and a passion for pushing boundaries, Grunenberg's contributions have revolutionized the way we approach pharmaceutical active ingredients.

Latest Patents:

Grunenberg's notable patent, "Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient," stands as a testament to his expertise in developing novel processes for essential pharmaceutical components.

Career Highlights:

Having secured 1 patent, Alfons Grunenberg is associated with Bayer Pharma Aktiengesellschaft, a renowned pharmaceutical company at the forefront of cutting-edge research and development. His dedication to enhancing pharmaceutical technologies has propelled Bayer Pharma Aktiengesellschaft to new heights of innovation and excellence.

Collaborations:

In his quest for groundbreaking discoveries, Grunenberg has collaborated closely with esteemed colleagues such as Johannes Platzek and Gunnar Garke. Together, they have synergized their talents and expertise to drive forward pioneering advancements in pharmaceutical science.

Conclusion:

In conclusion, Alfons Grunenberg's remarkable journey as an inventor exemplifies the power of creativity and perseverance in driving meaningful change within the pharmaceutical industry. His legacy serves as a beacon of inspiration for aspiring inventors and underscores the transformative impact of innovation in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.